AU2005251572B2 - Sterol enriched mixed lammelarity Amphotericin intercalating liposomes in saline and the process for their preparation - Google Patents

Sterol enriched mixed lammelarity Amphotericin intercalating liposomes in saline and the process for their preparation Download PDF

Info

Publication number
AU2005251572B2
AU2005251572B2 AU2005251572A AU2005251572A AU2005251572B2 AU 2005251572 B2 AU2005251572 B2 AU 2005251572B2 AU 2005251572 A AU2005251572 A AU 2005251572A AU 2005251572 A AU2005251572 A AU 2005251572A AU 2005251572 B2 AU2005251572 B2 AU 2005251572B2
Authority
AU
Australia
Prior art keywords
amphotericin
liposomes
intercalating
sterol
lamellarity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005251572A
Other languages
English (en)
Other versions
AU2005251572A1 (en
Inventor
Krishan Kumar Tripathi
Jitendra Nath Verma
Lily Verma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lifecare Innovations Pvt Ltd
Original Assignee
Lifecare Innovations Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifecare Innovations Pvt Ltd filed Critical Lifecare Innovations Pvt Ltd
Publication of AU2005251572A1 publication Critical patent/AU2005251572A1/en
Assigned to LIFECARE INNOVATIONS PVT. LTD reassignment LIFECARE INNOVATIONS PVT. LTD Request for Assignment Assignors: TRIPATHI, KRISHAN, VERMA, JITENDRA, VERMA, LILY
Application granted granted Critical
Publication of AU2005251572B2 publication Critical patent/AU2005251572B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
AU2005251572A 2004-06-11 2005-06-13 Sterol enriched mixed lammelarity Amphotericin intercalating liposomes in saline and the process for their preparation Ceased AU2005251572B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1113DE2004 2004-06-11
IN1113/DEL/2004 2004-06-11
PCT/IN2005/000193 WO2005120460A1 (en) 2004-06-11 2005-06-13 Sterol enriched mixed lammelarity amphotericin intercalating liposomes in saline and the process for their preparation

Publications (2)

Publication Number Publication Date
AU2005251572A1 AU2005251572A1 (en) 2005-12-22
AU2005251572B2 true AU2005251572B2 (en) 2010-03-11

Family

ID=34972096

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005251572A Ceased AU2005251572B2 (en) 2004-06-11 2005-06-13 Sterol enriched mixed lammelarity Amphotericin intercalating liposomes in saline and the process for their preparation

Country Status (9)

Country Link
US (1) US20070218119A1 (enExample)
EP (1) EP1771156B8 (enExample)
JP (1) JP4966855B2 (enExample)
CN (1) CN101014322A (enExample)
AT (1) ATE476965T1 (enExample)
AU (1) AU2005251572B2 (enExample)
BR (1) BRPI0511371A (enExample)
DE (1) DE602005022876D1 (enExample)
WO (1) WO2005120460A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1003990B1 (pt) * 2009-10-16 2021-09-14 Lifecare Innovations Pvt. Ltd Formulação para o tratamento de infecções fúngicas
CN108602025B (zh) 2016-03-04 2021-02-26 栗田工业株式会社 选择性透过膜及其制造方法、使用该选择性透过膜的水处理方法
PT3694526T (pt) 2017-10-11 2025-01-20 Univ Illinois Resgate independente do genótipo da fibrose quística com canais de bicarbonato de moléculas pequenas
IL315719A (en) 2022-03-21 2024-11-01 Univ Illinois Prosthetic assemblies of ion channels containing lipid-coated amphotericin B crystals

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766046A (en) * 1985-09-27 1988-08-23 Liposome Technology, Inc. Stabilized liposome/amphotericin composition and method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2134869A (en) * 1983-02-15 1984-08-22 Squibb & Sons Inc Method of preparing liposomes and products produced thereby
US4744989A (en) * 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766046A (en) * 1985-09-27 1988-08-23 Liposome Technology, Inc. Stabilized liposome/amphotericin composition and method

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MEHTA R. et al., Biochemica Et Biophysica Acta, 1984, vol. 770, no. 2, pp 230-234 *
SZOKA F. C Jr et al., Antimicrobial Agents and Chemotherapy, 1987, vol. 31, no. 3, pp 421-429 *

Also Published As

Publication number Publication date
EP1771156A1 (en) 2007-04-11
WO2005120460A1 (en) 2005-12-22
AU2005251572A1 (en) 2005-12-22
BRPI0511371A (pt) 2008-03-11
US20070218119A1 (en) 2007-09-20
JP2008501782A (ja) 2008-01-24
EP1771156B1 (en) 2010-08-11
CN101014322A (zh) 2007-08-08
JP4966855B2 (ja) 2012-07-04
ATE476965T1 (de) 2010-08-15
DE602005022876D1 (de) 2010-09-23
EP1771156B8 (en) 2010-09-15

Similar Documents

Publication Publication Date Title
CN101138550B (zh) 多种表面活性剂联合使用制备的混合胶束药物制剂及其制备方法
KR102115718B1 (ko) 대두 포스파티딜세린으로 제조된 코클리에이트
US7238366B1 (en) Submicron liposome suspensions obtained from preliposome lyophilizates
JP3202999B2 (ja) 肝移行性リポソーム製剤
EP1539102A2 (en) Pharmaceutically active lipid based formulation of sn38
Agrawal et al. Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters
EP0432117A1 (en) Composition for treatment of inflammation
Chance New developments in the chemotherapy of leishmaniasis
KR20170100680A (ko) 외이도염의 신속한 치료를 위한 방법 및 조성물
Lopez-Berestein et al. Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-O-stearoyl-N-acetylmuramyl-L-α-aminobutyryl-D-isoglutamine
EP1771156B1 (en) Sterol enriched mixed lamellarity amphotericin intercalating liposomes in saline and the process for their preparation
EP4501316A1 (en) Gemcitabine liposome pharmaceutical composition, preparation method therefor and use thereof
US20120207821A1 (en) Liposomal formulation and use thereof
US8298573B2 (en) Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs
US9011924B2 (en) Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
CN1739525A (zh) 一种新型的聚乙二醇衍生化磷脂包载前列腺素e1的纳米微粒给药系统
EP1313449B1 (en) Amphotericin b structured emulsion
WO2000009071A2 (en) A novel liposomal formulation useful in treatment of cancer and other proliferation diseases
JP3272736B2 (ja) リポソーム製剤
CA2957645A1 (en) Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intra vaginal delivery
WO1993023015A1 (en) Liposomal aminoglycoside compositions and process for their preparation
US20170281714A1 (en) Method of treatment using liposomally formulated reduced glutathione to cooperate with il-10 to modulate inflammatory response triggered in hiv+ and tb immune-compromised diabetic patients
EP1030653B1 (en) Dinitroaniline liposomal formulations and processes for their preparation
WO2013131164A1 (pt) Composição farmacêutica contendo lipossomas convencionais e lipossomas de circulação prolongada para o tratamento da leishmaniose visceral
WASAN et al. The development of liposomal amphotericin B: an historical perspective

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: LIFECARE INNOVATIONS PVT. LTD

Free format text: FORMER APPLICANT(S): TRIPATHI, KRISHAN; VERMA, LILY; VERMA, JITENDRA

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired